Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMILY N PRENDERGAST

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1780995803
CMS profile
670568
Location
MINNEAPOLIS, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$120.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Grant $120.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan, Inc. $120.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMILY N PRENDERGAST

NPI 1780995803 · CMS profile ID 670568

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

MINNEAPOLIS, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780995803?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMILY N PRENDERGAST, NPI 1780995803, CMS profile ID 670568. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780995803?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). EMILY N PRENDERGAST, NPI 1780995803, CMS profile ID 670568. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780995803?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
EMILY N PRENDERGAST, NPI 1780995803, CMS profile ID 670568, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1780995803?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $120.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan, Inc. $120.0010/19/2022 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889964605 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $1,800.00 1
PY2022 $120.00 1
PY2024 $4,385.36 22
PY2025 $3,304.08 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $40,059.40 13
PY2024 Principal investigator $34,813.04 7
PY2023 Principal investigator $305,678.61 18
PY2022 Principal investigator $385,361.71 71
PY2021 Principal investigator $620,544.15 127
PY2020 Principal investigator $1,117,220.38 160
PY2019 Principal investigator $1,317,552.79 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

160 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 12/28/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825019
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 12/28/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740827767
Principal investigator 1 GlaxoSmithKline, LLC. $915.00 12/16/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734917341
Principal investigator 1 GlaxoSmithKline, LLC. $78,677.00 12/15/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734926731
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 12/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835389
Principal investigator 1 Merck Sharp & Dohme Corporation $1,952.00 12/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835773
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 12/08/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825021
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 12/08/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740827769
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 11/24/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734915731
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 11/17/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740827593
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 11/17/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740827775
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834247
Principal investigator 1 Merck Sharp & Dohme Corporation $97.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834253
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834633
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834635
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834813
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834815
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834817
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834819
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834821
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834823
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835003
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835191
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835193
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835195
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835197
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835199
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835201
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835379
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835381
Principal investigator 1 Merck Sharp & Dohme Corporation $97.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835577
Principal investigator 1 Merck Sharp & Dohme Corporation $97.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835579
Principal investigator 1 Merck Sharp & Dohme Corporation $1,564.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835763
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 11/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835961
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 11/10/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734929003
Principal investigator 1 GlaxoSmithKline, LLC. $1,600.00 11/03/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734914697
Principal investigator 1 GlaxoSmithKline, LLC. $7,570.00 10/28/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734915395
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 10/28/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825403
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 10/28/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740827773
Principal investigator 1 GlaxoSmithKline, LLC. $2,713.00 10/27/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734911117
Principal investigator 1 Clovis Oncology, Inc. $31,411.25 10/26/2020 Non-covered Recipient Entity
Health Partners Institute
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 728177573
Principal investigator 1 GlaxoSmithKline, LLC. $14,605.00 10/20/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734918021
Principal investigator 1 GlaxoSmithKline, LLC. $3,412.02 10/19/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734925505
Principal investigator 1 Merck Sharp & Dohme Corporation $1,724.00 10/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835769
Principal investigator 1 Merck Sharp & Dohme Corporation $1,942.00 10/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835771
Principal investigator 1 Merck Sharp & Dohme Corporation $205.00 10/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835955
Principal investigator 1 GlaxoSmithKline, LLC. $7,434.00 10/14/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734915751
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 10/06/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825405
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 10/06/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740827591
Principal investigator 1 GlaxoSmithKline, LLC. $3,445.00 09/29/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734922319
Principal investigator 1 GlaxoSmithKline, LLC. $3,251.00 09/18/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734918951
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 09/16/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825217
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 09/16/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740827405
Principal investigator 1 GlaxoSmithKline, LLC. $21,790.00 09/15/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734911085
Principal investigator 1 Merck Sharp & Dohme Corporation $1,792.00 09/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740833863
Principal investigator 1 GlaxoSmithKline, LLC. $2,250.00 09/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734916319
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 09/09/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825407
Principal investigator 1 GlaxoSmithKline, LLC. $18,632.90 08/26/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734925503
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 08/26/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825213
Principal investigator 1 Merck Sharp & Dohme Corporation $376.49 08/26/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825219
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 08/26/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825593
Principal investigator 1 GlaxoSmithKline, LLC. $17,124.00 08/18/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734910687
Principal investigator 1 Merck Sharp & Dohme Corporation $1,200.00 08/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835569
Principal investigator 1 Merck Sharp & Dohme Corporation $1,200.00 08/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835751
Principal investigator 1 Merck Sharp & Dohme Corporation $1,200.00 08/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835753
Principal investigator 1 Merck Sharp & Dohme Corporation $1,280.00 08/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835759
Principal investigator 1 Merck Sharp & Dohme Corporation $730.00 08/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836333
Principal investigator 1 Merck Sharp & Dohme Corporation $1,724.00 08/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836521
Principal investigator 1 Clovis Oncology, Inc. $25,230.00 08/10/2020 Non-covered Recipient Entity
Health Partners Institute
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 728177571
Principal investigator 1 GlaxoSmithKline, LLC. $3,113.68 08/07/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734919399
Principal investigator 1 Merck Sharp & Dohme Corporation $321.85 08/07/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740745621
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 08/05/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825215
Principal investigator 1 Merck Sharp & Dohme Corporation $376.49 08/05/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825401
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 08/05/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740827399
Principal investigator 1 GlaxoSmithKline, LLC. $1,645.00 08/04/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734915749
Principal investigator 1 GlaxoSmithKline, LLC. $15,500.00 07/28/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734922317
Principal investigator 1 GlaxoSmithKline, LLC. $22,243.00 07/21/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734921789
Principal investigator 1 Merck Sharp & Dohme Corporation $1,909.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740833865
Principal investigator 1 Merck Sharp & Dohme Corporation $2,000.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740833867
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740833871
Principal investigator 1 Merck Sharp & Dohme Corporation $2,142.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835375
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835563
Principal investigator 1 Merck Sharp & Dohme Corporation $1,120.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835565
Principal investigator 1 Merck Sharp & Dohme Corporation $1,135.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835567
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835943
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835945
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835953
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836133
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836135
Principal investigator 1 Merck Sharp & Dohme Corporation $1,625.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836139
Principal investigator 1 Merck Sharp & Dohme Corporation $1,638.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836141
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836327
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836329
Principal investigator 1 Merck Sharp & Dohme Corporation $1,004.00 07/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836515
Principal investigator 1 GlaxoSmithKline, LLC. $4,356.00 07/14/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734911749
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 07/14/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825209
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 07/14/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825211
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 07/14/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740827589
Principal investigator 1 GlaxoSmithKline, LLC. $3,450.00 07/13/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734915069
Principal investigator 1 GlaxoSmithKline, LLC. $103,096.00 07/07/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734913651
Principal investigator 1 Clovis Oncology, Inc. $15,000.00 07/01/2020 Non-covered Recipient Entity
HEALTHPARTNERS INSTITUTE
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) No dispute reported 06/30/2026 728176897
Principal investigator 1 Merck Sharp & Dohme Corporation $874.70 06/30/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740745625
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 06/23/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740745629
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 06/23/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825023
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 06/23/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825025
Principal investigator 1 GlaxoSmithKline, LLC. $1,880.00 06/16/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734911541
Principal investigator 1 Merck Sharp & Dohme Corporation $1,382.00 06/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834425
Principal investigator 1 Merck Sharp & Dohme Corporation $1,909.00 06/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834793
Principal investigator 1 Merck Sharp & Dohme Corporation $1,909.00 06/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834795
Principal investigator 1 Merck Sharp & Dohme Corporation $1,909.00 06/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834807
Principal investigator 1 Merck Sharp & Dohme Corporation $150.00 06/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836493
Principal investigator 1 Merck Sharp & Dohme Corporation $1,280.00 06/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836497
Principal investigator 1 GlaxoSmithKline, LLC. $29,012.25 06/11/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734919159
Principal investigator 1 Clovis Oncology, Inc. $66,140.00 06/08/2020 Non-covered Recipient Entity
Health Partners Institute
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 728177569
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 06/03/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740745953
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 06/03/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825027
Principal investigator 1 Merck Sharp & Dohme Corporation $461.49 06/03/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740825029
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 05/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740833847
Principal investigator 1 Merck Sharp & Dohme Corporation $200.00 05/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834989
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 05/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836111
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 05/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836113
Principal investigator 1 Merck Sharp & Dohme Corporation $1,164.00 05/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836303
Principal investigator 1 GlaxoSmithKline, LLC. $3,982.51 05/07/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734924979
Principal investigator 1 GlaxoSmithKline, LLC. $70,574.00 04/28/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734922059
Principal investigator 1 GlaxoSmithKline, LLC. $645.00 04/16/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734923099
Principal investigator 1 Merck Sharp & Dohme Corporation $730.00 04/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834237
Principal investigator 1 Merck Sharp & Dohme Corporation $1,232.00 04/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834981
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 04/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835185
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 04/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835929
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 04/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836109
Principal investigator 1 Merck Sharp & Dohme Corporation $1,164.00 04/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836301
Principal investigator 1 GlaxoSmithKline, LLC. $49,640.00 04/07/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734910683
Principal investigator 1 Merck Sharp & Dohme Corporation $1,542.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834031
Principal investigator 1 Merck Sharp & Dohme Corporation $1,909.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834605
Principal investigator 1 Merck Sharp & Dohme Corporation $423.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834791
Principal investigator 1 Merck Sharp & Dohme Corporation $100.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834985
Principal investigator 1 Merck Sharp & Dohme Corporation $200.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740834987
Principal investigator 1 Merck Sharp & Dohme Corporation $2,000.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835167
Principal investigator 1 Merck Sharp & Dohme Corporation $1,280.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835359
Principal investigator 1 Merck Sharp & Dohme Corporation $1,115.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835535
Principal investigator 1 Merck Sharp & Dohme Corporation $56.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835549
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835727
Principal investigator 1 Merck Sharp & Dohme Corporation $1,120.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835729
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835921
Principal investigator 1 Merck Sharp & Dohme Corporation $150.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836115
Principal investigator 1 Merck Sharp & Dohme Corporation $150.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836117
Principal investigator 1 Merck Sharp & Dohme Corporation $150.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836119
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836131
Principal investigator 1 Merck Sharp & Dohme Corporation $1,200.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836305
Principal investigator 1 Merck Sharp & Dohme Corporation $1,200.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836307
Principal investigator 1 Merck Sharp & Dohme Corporation $1,200.00 03/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836309
Principal investigator 1 GlaxoSmithKline, LLC. $3,718.00 03/12/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC-CHICAGO-UNITED
A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SA No dispute reported 06/30/2026 734926769
Principal investigator 1 Merck Sharp & Dohme Corporation $756.20 03/10/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740745623
Principal investigator 1 GlaxoSmithKline, LLC. $338,353.00 02/19/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734912207
Principal investigator 1 Merck Sharp & Dohme Corporation $1,025.00 02/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740836499
Principal investigator 1 Merck Sharp & Dohme Corporation $206.80 01/28/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, PA
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740827225
Principal investigator 1 Merck Sharp & Dohme Corporation $213.00 01/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835171
Principal investigator 1 Merck Sharp & Dohme Corporation $213.00 01/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835173
Principal investigator 1 Merck Sharp & Dohme Corporation $213.00 01/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835175
Principal investigator 1 Merck Sharp & Dohme Corporation $213.00 01/15/2020 Non-covered Recipient Entity
MINNESOTA ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740835935